drTarget portfolio target-disease associations for cardiovascular diseases

OpenTargets offers > 19k target-disease associations from PChem targets suitable for virtual screening based in OpenTargets scores for cardiovascular disorders. See here the best scored pairs.

Target-disease associations for cardiovascular disorders.

Check best scored target-disease associations in table:

PubChemAssay	program	diseaseName	assayType	testedComopunds	activeCompounds	weightedScore	weightedEvidence
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	congestive heart failure	targetBased	335239	801	0.351769550612851	13
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	congestive heart failure	targetBased	335238	390	0.351769550612851	13
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	congestive heart failure	targetBased	335531	328	0.527581485904718	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	congestive heart failure	targetBased	339297	1446	0.651600017001438	50
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	congestive heart failure	targetBased	76168	1231	0.613250657387013	22
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	atrial fibrillation	targetBased	305610	3878	0.541829820157546	315
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	atrial fibrillation	targetBased	305610	1082	0.541829820157546	315
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	atrial fibrillation	targetBased	305610	1552	0.802439563669594	261
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	atrial fibrillation	targetBased	343666	1267	0.802439563669594	261
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	atrial fibrillation	targetBased	342084	3260	0.802439563669594	261
Factor XIa 1536 HTS	F11_modulation	atrial fibrillation	targetBased	218707	302	0.357517588702518	23
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	atrial fibrillation	targetBased	405130	6428	0.420727514448716	59
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	atrial fibrillation	targetBased	373462	23	0.420727514448716	59
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	atrial fibrillation	targetBased	405130	6428	0.420727514448716	59
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	atrial fibrillation	targetBased	305610	2592	0.783777345668684	234
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	atrial fibrillation	targetBased	86095	1114	0.539624047756777	26
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	atrial fibrillation	targetBased	276265	806	0.424659611479414	15
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	atrial fibrillation	targetBased	335531	328	0.670494073297023	97
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	atrial fibrillation	targetBased	339297	1446	0.656155319809075	74
Primary biochemical high-throughput screening assay for inhibitors of Focal Adhesion Kinase (FAK)	PTK2	atrial fibrillation	targetBased	96879	811	0.348342323787707	21
Thrombin 1536 HTS	F2_modulation	atrial fibrillation	targetBased	217233	557	0.673166313522287	170
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	atrial fibrillation	pathwayBased	271402	1048	0.334098389930725	11
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	atrial fibrillation	pathwayBased	267412	5703	0.334098389930725	11
qHTS Assay for Tau Filament Binding	MAPT	atrial fibrillation	targetBased	69668	1391	0.334098389930725	11
HCS assay for microtubule stabilizers	TUBB	atrial fibrillation	targetBased	195821	1625	0.435406862853961	17
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hypertension	targetBased	86095	1442	0.421637500320573	54
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hypertension	targetBased	86095	1151	0.421637500320573	54
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hypertension	targetBased	394050	3624	0.50567174512419	25
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	hypertension	targetBased	306502	3633	0.304005649962294	22
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	hypertension	targetBased	335180	1022	0.304005649962294	22
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	99314	335	0.383046446409166	146
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196176	782	0.383046446409166	146
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	99314	390	0.383046446409166	146
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196177	811	0.383046446409166	146
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196176	670	0.383046446409166	146
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hypertension	targetBased	196177	519	0.383046446409166	146
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hypertension	targetBased	86095	1114	0.293898359792957	13
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	hypertension	targetBased	335531	328	0.784665512239552	1291
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	hypertension	targetBased	335777	499	0.436366272016687	11
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hypertension	targetBased	339297	1446	0.668853049947844	367
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	hypertension	targetBased	76168	1231	0.565070002375135	27
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	hypertension	targetBased	339674	2841	0.674429375550638	181
Allosteric Modulators of D1 Receptors: Primary Screen	D1	hypertension	targetBased	57705	3413	0.512185146348314	6
Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS	D1_activators	hypertension	targetBased	361330	3713	0.512185146348314	6
Antagonist of Human D 1 Dopamine Receptor: qHTS	D1_inhibitors	hypertension	targetBased	355805	11440	0.512185146348314	6
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	hypertension	targetBased	104728	4230	0.343100200487281	7
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	hypertension	targetBased	316642	617	0.542390725803381	20
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	myocardial infarction	targetBased	305610	1552	0.359248840869334	21
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	myocardial infarction	targetBased	343666	1267	0.359248840869334	21
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	myocardial infarction	targetBased	342084	3260	0.359248840869334	21
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	myocardial infarction	targetBased	319204	3065	0.379088804549568	72
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	myocardial infarction	targetBased	316970	306	0.379088804549568	72
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	myocardial infarction	targetBased	86095	1442	0.339277341652025	118
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	myocardial infarction	targetBased	86095	1151	0.339277341652025	118
qHTS for Inhibitors of TGF-b	TGFB1	myocardial infarction	pathwayBased	403345	4970	0.32105894859906	913
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	myocardial infarction	targetBased	394050	3624	0.376253753005692	31
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	myocardial infarction	targetBased	335239	991	0.578271542280002	11
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	myocardial infarction	targetBased	335239	695	0.578271542280002	11
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	myocardial infarction	targetBased	405130	6428	0.555353879811961	333
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	myocardial infarction	targetBased	373462	23	0.555353879811961	333
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	myocardial infarction	targetBased	405130	6428	0.555353879811961	333
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	myocardial infarction	targetBased	325247	1021	0.418499778482598	30
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	myocardial infarction	targetBased	59788	212	0.408625509213493	11
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	myocardial infarction	targetBased	86095	1114	0.294234899440742	38
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	myocardial infarction	targetBased	359518	300	0.439839067210336	6
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	myocardial infarction	targetBased	335652	1779	0.439839067210336	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	myocardial infarction	targetBased	362274	1056	0.439839067210336	6
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	myocardial infarction	targetBased	336308	6862	0.439839067210336	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	myocardial infarction	targetBased	357537	806	0.439839067210336	6
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	myocardial infarction	targetBased	339887	1178	0.439839067210336	6
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	myocardial infarction	targetBased	276265	806	0.355475691441654	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	myocardial infarction	targetBased	335531	328	0.659633610265158	76
HTS of Smad transcription factor inhibitors	SMAD3	myocardial infarction	targetBased	88033	251	0.430244164060686	118
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	myocardial infarction	targetBased	339297	1446	0.670611093215975	227
Thrombin 1536 HTS	F2_modulation	myocardial infarction	targetBased	217233	557	0.599407497681816	152
HCS assay for microtubule stabilizers	TUBB	myocardial infarction	targetBased	195821	1625	0.581891484264645	13
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	myocardial infarction	targetBased	358434	2554	0.307714483936324	20
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	coronary artery disease	targetBased	319204	3065	0.513875832928574	147
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	coronary artery disease	targetBased	316970	306	0.513875832928574	147
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	coronary artery disease	targetBased	86095	1442	0.470428412517821	183
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	coronary artery disease	targetBased	86095	1151	0.470428412517821	183
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	coronary artery disease	targetBased	363803	2412	0.414572866969997	13
qHTS for Inhibitors of TGF-b	TGFB1	coronary artery disease	pathwayBased	403345	4970	0.376449062041855	224
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	coronary artery disease	targetBased	394050	3624	0.387861128233729	70
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	coronary artery disease	targetBased	335239	991	0.592008485412301	10
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	coronary artery disease	targetBased	335239	695	0.592008485412301	10
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	coronary artery disease	targetBased	405130	6428	0.384469301589397	153
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	coronary artery disease	targetBased	373462	23	0.384469301589397	153
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	coronary artery disease	targetBased	405130	6428	0.384469301589397	153
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	coronary artery disease	targetBased	325247	1021	0.411957572558763	21
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	coronary artery disease	targetBased	369953	3123	0.266582952262131	6
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	coronary artery disease	targetBased	344733	7043	0.277611256410927	45
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	coronary artery disease	targetBased	335239	801	0.452107414048022	599
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	coronary artery disease	targetBased	335238	390	0.452107414048022	599
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	99314	335	0.538184411305718	204
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196176	782	0.538184411305718	204
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	99314	390	0.538184411305718	204
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196177	811	0.538184411305718	204
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196176	670	0.538184411305718	204
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	coronary artery disease	targetBased	196177	519	0.538184411305718	204
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	coronary artery disease	targetBased	86095	1114	0.440700143257634	29
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	coronary artery disease	targetBased	276265	806	0.375083156200627	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	coronary artery disease	targetBased	335531	328	0.666430352142117	442
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	coronary artery disease	targetBased	343467	1710	0.445363479109043	10
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	coronary artery disease	targetBased	356160	3470	0.39314131155056	20
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	coronary artery disease	targetBased	356160	1703	0.39314131155056	20
HTS of Smad transcription factor inhibitors	SMAD3	coronary artery disease	targetBased	88033	251	0.552484115357613	54
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	coronary artery disease	targetBased	339297	1446	0.614742335189791	48
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	coronary artery disease	targetBased	76168	1231	0.435439202613319	10
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	coronary artery disease	targetBased	305610	3794	0.601498428437273	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	coronary artery disease	targetBased	339674	2841	0.601498428437273	11
Thrombin 1536 HTS	F2_modulation	coronary artery disease	targetBased	217233	557	0.649046640119132	118
HCS assay for microtubule stabilizers	TUBB	coronary artery disease	targetBased	195821	1625	0.641765925028877	28
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	coronary artery disease	targetBased	316642	617	0.440994765306032	15
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	coronary artery disease	targetBased	343468	734	0.513031657023707	18
HTS of Smad transcription factor inhibitors	SMAD3	aortic aneurysm	targetBased	88033	251	0.501060091567992	63
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	heart disease	targetBased	305610	3878	0.336382820641752	2001
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	heart disease	targetBased	305610	1082	0.336382820641752	2001
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	heart disease	targetBased	305610	1552	0.5744892428341	1627
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	heart disease	targetBased	343666	1267	0.5744892428341	1627
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	heart disease	targetBased	342084	3260	0.5744892428341	1627
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	heart disease	targetBased	86095	1442	0.491789587663523	249
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	heart disease	targetBased	86095	1151	0.491789587663523	249
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	heart disease	targetBased	335239	991	0.610101705726402	24
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	heart disease	targetBased	335239	695	0.610101705726402	24
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	heart disease	targetBased	305610	2592	0.337779720181742	1164
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart disease	targetBased	335239	801	0.388259441397677	2598
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart disease	targetBased	335238	390	0.388259441397677	2598
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	heart disease	targetBased	86095	1114	0.482009080109138	883
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	heart disease	targetBased	276265	806	0.420322702524328	19
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	heart disease	targetBased	335531	328	0.593237032510884	412
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	heart disease	targetBased	324747	813	0.400381769027036	16
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	heart disease	targetBased	339297	1446	0.48950855104779	265
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	heart disease	targetBased	76168	1231	0.494409718878496	153
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	heart disease	targetBased	305610	3794	0.494040568817361	17
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	heart disease	targetBased	199169	715	0.329286693560426	3157
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	heart disease	targetBased	302297	1165	0.329286693560426	3157
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	heart disease	targetBased	339674	2841	0.527003319061794	45
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	heart disease	targetBased	369953	760	0.442491548090815	45
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	heart disease	targetBased	369953	498	0.442491548090815	45
Glucocerebrosidase	GBA1	heart disease	targetBased	48118	549	0.295851471883425	192
Thrombin 1536 HTS	F2_modulation	heart disease	targetBased	217233	557	0.439971747608358	209
HCS assay for microtubule stabilizers	TUBB	heart disease	targetBased	195821	1625	0.274582164904876	34
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	heart failure	targetBased	305610	1552	0.547212563446782	10
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	heart failure	targetBased	343666	1267	0.547212563446782	10
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	heart failure	targetBased	342084	3260	0.547212563446782	10
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	heart failure	targetBased	394050	3624	0.537056766771359	15
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart failure	targetBased	335239	801	0.64314305161478	117
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart failure	targetBased	335238	390	0.64314305161478	117
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	heart failure	targetBased	335531	328	0.645161667574849	44
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	heart failure	targetBased	324747	813	0.582667962238769	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	heart failure	targetBased	339297	1446	0.660625331502392	81
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	heart failure	targetBased	76168	1231	0.597582643776577	29
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1	relaxinInhibitors	heart failure	targetBased	350177	2058	0.402671409429789	15
qHTS Assay for Antagonists of the Relaxin Receptor RXFP1Taking the negative queue for PMs	relaxin PMs	heart failure	targetBased	350177	2058	0.402671409429789	15
qHTS Assay for Agonists of the Relaxin Receptor RXFP1	RXFP1	heart failure	targetBased	362198	1084	0.402671409429789	15
HCS assay for microtubule stabilizers	TUBB	heart failure	targetBased	195821	1625	0.366142497875815	6
Factor XIa 1536 HTS	F11_modulation	pulmonary embolism	targetBased	218707	302	0.529837764887743	9
Thrombin 1536 HTS	F2_modulation	pulmonary embolism	targetBased	217233	557	0.630479729710024	26
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	atrial flutter	targetBased	305610	1552	0.561048672319976	20
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	atrial flutter	targetBased	343666	1267	0.561048672319976	20
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	atrial flutter	targetBased	342084	3260	0.561048672319976	20
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	atrial flutter	targetBased	335531	328	0.529463532047883	9
qHTS for Inhibitors of TGF-b	TGFB1	angina pectoris	pathwayBased	403345	4970	0.291232525916009	30
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	angina pectoris	targetBased	335531	328	0.662387380315676	134
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	angina pectoris	targetBased	339297	1446	0.615165132654478	23
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	atherosclerosis	pathwayBased	362051	17187	0.307719686617144	1501
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	99314	335	0.431128940589068	990
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196176	782	0.431128940589068	990
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	99314	390	0.431128940589068	990
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196177	811	0.431128940589068	990
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196176	670	0.431128940589068	990
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	atherosclerosis	targetBased	196177	519	0.431128940589068	990
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	atherosclerosis	targetBased	326024	4934	0.344157854845113	518
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	atherosclerosis	targetBased	335531	328	0.388681972644248	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	atherosclerosis	targetBased	339297	1446	0.523118463288717	14
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	left ventricular hypertrophy	targetBased	394050	3624	0.28891104408561	29
HCS assay for microtubule stabilizers	TUBB	Coronary Restenosis	targetBased	195821	1625	0.310920784693153	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Coronary Vasospasm	targetBased	335531	328	0.642829168666001	119
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	ventricular fibrillation	targetBased	305610	1552	0.760259527871274	51
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	ventricular fibrillation	targetBased	343666	1267	0.760259527871274	51
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	ventricular fibrillation	targetBased	342084	3260	0.760259527871274	51
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ventricular fibrillation	targetBased	339297	1446	0.411238352018758	12
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	vascular disease	targetBased	86095	1442	0.259756508590195	420
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	vascular disease	targetBased	86095	1151	0.259756508590195	420
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	vascular disease	targetBased	217959	2390	0.259257178462855	247
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	vascular disease	pathwayBased	70898	707	0.26037973565382	72
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	vascular disease	pathwayBased	131324	544	0.26037973565382	72
qHTS assay for re-activators of p53 using a Luc reporter	TP53	vascular disease	pathwayBased	321427	201	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	54509	528	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	54513	338	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	125394	1890	0.308282010064809	737
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	vascular disease	targetBased	124022	1156	0.308282010064809	737
Primary screen for compounds that activate Alzheimer's amyloid precursor	APP_inhibitors	vascular disease	pathwayBased	193400	1987	0.322472728273551	337
Primary screen for compounds that inhibit Alzheimer's amyloid precursor protein (APP) translation	APP_inhibitors	vascular disease	pathwayBased	193714	1590	0.322472728273551	337
qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: Primary Screen	APP_inhibitors	vascular disease	targetBased	404343	257	0.322472728273551	337
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	vascular disease	targetBased	335531	328	0.333129665796641	710
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1)	HTRA1	vascular disease	targetBased	343467	1710	0.303404291721427	121
HTS of Smad transcription factor inhibitors	SMAD3	vascular disease	targetBased	88033	251	0.31738553424318	944
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	vascular disease	targetBased	193542	587	0.259830615135327	68
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	vascular disease	targetBased	339297	1446	0.256542920788158	346
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	vascular disease	targetBased	339674	2841	0.311051929154863	182
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	vascular disease	targetBased	369953	760	0.25398423452813	69
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	vascular disease	targetBased	369953	498	0.25398423452813	69
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	vascular disease	targetBased	194628	267	0.281944830858339	35
Thrombin 1536 HTS	F2_modulation	vascular disease	targetBased	217233	557	0.278048642860817	660
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	peripheral arterial disease	targetBased	363803	2412	0.541518657430405	12
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	peripheral arterial disease	targetBased	394050	3624	0.507918611603607	9
HCS assay for microtubule stabilizers	TUBB	peripheral arterial disease	targetBased	195821	1625	0.366953918967478	8
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	cardiac arrhythmia	targetBased	305610	3878	0.717418405216669	970
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	cardiac arrhythmia	targetBased	305610	1082	0.717418405216669	970
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	cardiac arrhythmia	targetBased	305610	1552	0.815852504474459	1310
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	cardiac arrhythmia	targetBased	343666	1267	0.815852504474459	1310
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	cardiac arrhythmia	targetBased	342084	3260	0.815852504474459	1310
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	cardiac arrhythmia	targetBased	363803	2412	0.539628835168446	7
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	cardiac arrhythmia	targetBased	305610	2592	0.597082684094759	166
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	cardiac arrhythmia	targetBased	359518	300	0.542720161698728	8
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	cardiac arrhythmia	targetBased	335652	1779	0.542720161698728	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	cardiac arrhythmia	targetBased	362274	1056	0.542720161698728	8
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	cardiac arrhythmia	targetBased	336308	6862	0.542720161698728	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	cardiac arrhythmia	targetBased	357537	806	0.542720161698728	8
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	cardiac arrhythmia	targetBased	339887	1178	0.542720161698728	8
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	cardiac arrhythmia	targetBased	335531	328	0.604597373994676	52
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	cardiac arrhythmia	targetBased	359207	1189	0.578250225184157	7
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	cardiac arrhythmia	targetBased	63676	1938	0.578250225184157	7
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	cardiac arrhythmia	targetBased	359207	316	0.578250225184157	7
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	cardiac arrhythmia	targetBased	63656	2179	0.578250225184157	7
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	cardiac arrhythmia	targetBased	359207	4555	0.578250225184157	7
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	cardiac arrhythmia	targetBased	363803	502	0.580213188041739	7
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	cardiac arrhythmia	targetBased	363803	2629	0.580213188041739	7
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	cardiac arrhythmia	targetBased	363803	1450	0.580213188041739	7
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	cardiac arrhythmia	targetBased	363803	698	0.577168330395272	6
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	cardiac arrhythmia	targetBased	363803	2133	0.577168330395272	6
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	cardiac arrhythmia	targetBased	363803	1081	0.577168330395272	6
qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization	MAPT	cardiac arrhythmia	pathwayBased	271402	1048	0.361351848709784	22
qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding	MAPT	cardiac arrhythmia	pathwayBased	267412	5703	0.361351848709784	22
qHTS Assay for Tau Filament Binding	MAPT	cardiac arrhythmia	targetBased	69668	1391	0.361351848709784	22
HCS assay for microtubule stabilizers	TUBB	cardiac arrhythmia	targetBased	195821	1625	0.335410282414491	7
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	blood pressure	targetBased	394050	3624	0.308553519683985	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	blood pressure	targetBased	335531	328	0.406928483573352	17
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	blood pressure	targetBased	339674	2841	0.445041065782812	28
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	electrocardiography	targetBased	305610	3878	0.590050079226244	203
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	electrocardiography	targetBased	305610	1082	0.590050079226244	203
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	electrocardiography	targetBased	305610	1552	0.431082166107401	54
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	electrocardiography	targetBased	343666	1267	0.431082166107401	54
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	electrocardiography	targetBased	342084	3260	0.431082166107401	54
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	electrocardiography	targetBased	363840	2624	0.527705179950392	17
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	electrocardiography	targetBased	305610	2592	0.451022018543145	59
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	electrocardiography	targetBased	368927	620	0.445812129516972	35
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	sudden cardiac arrest	targetBased	305610	1552	0.459752810561344	20
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	sudden cardiac arrest	targetBased	343666	1267	0.459752810561344	20
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	sudden cardiac arrest	targetBased	342084	3260	0.459752810561344	20
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	sudden cardiac arrest	targetBased	339297	1446	0.647528186233432	36
HTS of Smad transcription factor inhibitors	SMAD3	thoracic aortic aneurysm	targetBased	88033	251	0.329835797553122	35
Factor XIa 1536 HTS	F11_modulation	venous thromboembolism	targetBased	218707	302	0.660405165989325	101
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	electrocardiography	targetBased	276265	806	0.487395272317986	19
Thrombin 1536 HTS	F2_modulation	venous thromboembolism	targetBased	217233	557	0.704341553035662	518
HCS assay for microtubule stabilizers	TUBB	vascular disease	targetBased	195821	1625	0.272405235445476	36
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	cardiac arrhythmia	targetBased	339297	1446	0.637646823165619	67
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	QT interval	targetBased	305610	3878	0.596223074271587	24
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	QT interval	targetBased	305610	1082	0.596223074271587	24
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	QT interval	targetBased	305610	1552	0.449874560758587	18
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	QT interval	targetBased	343666	1267	0.449874560758587	18
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	QT interval	targetBased	342084	3260	0.449874560758587	18
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	QT interval	targetBased	305610	2592	0.348212042945037	12
HTS of Smad transcription factor inhibitors	SMAD3	intraocular pressure measurement	targetBased	88033	251	0.473819659941471	9
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	cardiac troponin T measurement	targetBased	368927	620	0.429531803958325	6
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	congenital heart disease	targetBased	305610	1552	0.27185250121656	332
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	congenital heart disease	targetBased	343666	1267	0.27185250121656	332
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	congenital heart disease	targetBased	342084	3260	0.27185250121656	332
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	congenital heart disease	targetBased	359207	1432	0.523986132818436	18
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	congenital heart disease	pathwayBased	70898	707	0.532266653827459	10
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	congenital heart disease	pathwayBased	131324	544	0.532266653827459	10
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	congenital heart disease	targetBased	339297	1446	0.355696532380639	8
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	congenital heart disease	targetBased	339674	2841	0.516813251834099	7
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	congenital heart disease	targetBased	369953	2602	0.798914888419431	147
Factor XIa 1536 HTS	F11_modulation	acute coronary syndrome	targetBased	218707	302	0.284450312827731	11
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	pulse pressure measurement	targetBased	86095	1442	0.465211580389372	11
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	pulse pressure measurement	targetBased	86095	1151	0.465211580389372	11
Luminescence cell-based high throughput primary assay to identify inhibitors of TEAD-YAP interaction.	YAP1	pulse pressure measurement	targetBased	639428	9218	0.508571324863295	6
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	acute coronary syndrome	targetBased	405130	6428	0.286544845943286	26
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	acute coronary syndrome	targetBased	373462	23	0.286544845943286	26
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	acute coronary syndrome	targetBased	405130	6428	0.286544845943286	26
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	acute coronary syndrome	targetBased	326024	4934	0.288472534590608	80
CYP2C19 Assay	CYP2C19_inhibitors	acute coronary syndrome	targetBased	95857	20295	0.466037961739569	216
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	acute coronary syndrome	targetBased	339297	1446	0.554062551323282	11
Thrombin 1536 HTS	F2_modulation	acute coronary syndrome	targetBased	217233	557	0.58681113834509	26
HCS assay for microtubule stabilizers	TUBB	acute coronary syndrome	targetBased	195821	1625	0.584323923650328	11
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	pulse pressure measurement	targetBased	339674	2841	0.44919567405545	14
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	pulse pressure measurement	targetBased	361330	651	0.453922410273476	6
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	pulse pressure measurement	targetBased	361330	2424	0.453922410273476	6
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hypotension	targetBased	335239	991	0.562382434947179	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hypotension	targetBased	335239	695	0.562382434947179	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hypotension	targetBased	339297	1446	0.6612423935077	103
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	orthostatic hypotension	targetBased	339297	1446	0.549035277361439	18
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	ventricular tachycardia	targetBased	305610	1552	0.6948342910003	133
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	ventricular tachycardia	targetBased	343666	1267	0.6948342910003	133
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	ventricular tachycardia	targetBased	342084	3260	0.6948342910003	133
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	ventricular tachycardia	targetBased	363803	2412	0.577574040941104	8
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	ventricular tachycardia	targetBased	359518	300	0.577168330395272	6
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	ventricular tachycardia	targetBased	335652	1779	0.577168330395272	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	ventricular tachycardia	targetBased	362274	1056	0.577168330395272	6
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	ventricular tachycardia	targetBased	336308	6862	0.577168330395272	6
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	ventricular tachycardia	targetBased	357537	806	0.577168330395272	6
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	ventricular tachycardia	targetBased	339887	1178	0.577168330395272	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ventricular tachycardia	targetBased	339297	1446	0.595189466920042	12
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	diastolic blood pressure	targetBased	86095	1442	0.451433217156287	6
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	diastolic blood pressure	targetBased	86095	1151	0.451433217156287	6
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	diastolic blood pressure	targetBased	363840	2624	0.393552178253481	9
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	diastolic blood pressure	targetBased	335531	328	0.470326091275314	14
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	diastolic blood pressure	targetBased	339674	2841	0.494806026280812	27
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	mean arterial pressure	targetBased	335531	328	0.450938883450173	8
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	mean arterial pressure	targetBased	339674	2841	0.448642022948897	12
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	diastolic blood pressure	targetBased	362026	1074	0.425250264145875	23
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	diastolic blood pressure	targetBased	362577	2709	0.425250264145875	23
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	diastolic blood pressure	targetBased	331671	10022	0.343307910677457	8
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	diastolic blood pressure	targetBased	358434	2554	0.298344540355862	47
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	pericarditis	pathwayBased	362051	17187	0.549333638497012	69
HCS assay for microtubule stabilizers	TUBB	pericarditis	targetBased	195821	1625	0.52560928186248	6
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	acute myocardial infarction	targetBased	405130	6428	0.365976586519998	53
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	acute myocardial infarction	targetBased	373462	23	0.365976586519998	53
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	acute myocardial infarction	targetBased	405130	6428	0.365976586519998	53
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	99314	335	0.427547631514323	65
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196176	782	0.427547631514323	65
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	99314	390	0.427547631514323	65
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196177	811	0.427547631514323	65
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196176	670	0.427547631514323	65
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	acute myocardial infarction	targetBased	196177	519	0.427547631514323	65
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	acute myocardial infarction	targetBased	339297	1446	0.510726398888352	17
Thrombin 1536 HTS	F2_modulation	acute myocardial infarction	targetBased	217233	557	0.496166108771324	59
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart valve disease	targetBased	335239	801	0.443766096667661	13
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	heart valve disease	targetBased	335238	390	0.443766096667661	13
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	ST Elevation Myocardial Infarction	targetBased	335239	801	0.28904568668655	48
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	ST Elevation Myocardial Infarction	targetBased	335238	390	0.28904568668655	48
Thrombin 1536 HTS	F2_modulation	ST Elevation Myocardial Infarction	targetBased	217233	557	0.593802462774375	9
HCS assay for microtubule stabilizers	TUBB	ST Elevation Myocardial Infarction	targetBased	195821	1625	0.539555581875448	6
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	cardiac arrest	targetBased	305610	1552	0.515630405814729	31
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	cardiac arrest	targetBased	343666	1267	0.515630405814729	31
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	cardiac arrest	targetBased	342084	3260	0.515630405814729	31
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	cardiac arrest	targetBased	324747	813	0.529763004236026	10
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	cardiac arrest	targetBased	339297	1446	0.565626365447611	27
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Agents acting on the renin-angiotensin system use measurement	targetBased	335531	328	0.443260371744578	6
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Prinzmetal's angina	targetBased	335531	328	0.664977476876164	306
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	atrial heart septal defect	targetBased	344733	7043	0.300714231973763	11
uHTS identification of small molecule modulators of NR3A	GRIN3A	cerebral atherosclerosis	targetBased	339772	8480	0.638992421523723	21
Thrombin 1536 HTS	F2_modulation	intermediate coronary syndrome	targetBased	217233	557	0.543359118242622	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	Myocardial Ischemia	targetBased	86095	1442	0.440369982475793	47
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	Myocardial Ischemia	targetBased	86095	1151	0.440369982475793	47
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Myocardial Ischemia	targetBased	86095	1114	0.423950615788154	14
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Myocardial Ischemia	targetBased	335531	328	0.574534968426493	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Myocardial Ischemia	targetBased	339297	1446	0.434244558165963	29
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity	SCARB1	Myocardial Ischemia	targetBased	319204	3065	0.33411871853546	9
HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity	SCARB1	Myocardial Ischemia	targetBased	316970	306	0.33411871853546	9
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Wolff-Parkinson-White Syndrome	targetBased	305610	3878	0.385390364097753	8
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Wolff-Parkinson-White Syndrome	targetBased	305610	1082	0.385390364097753	8
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	systolic heart failure	targetBased	335239	801	0.407578504803233	8
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	systolic heart failure	targetBased	335238	390	0.407578504803233	8
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH)	PLA2G7	endothelial dysfunction	targetBased	326024	4934	0.289018312328131	68
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Prolonged QT interval	targetBased	305610	3878	0.734109946020632	2070
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Prolonged QT interval	targetBased	305610	1082	0.734109946020632	2070
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Prolonged QT interval	targetBased	305610	1552	0.734041769977036	3500
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Prolonged QT interval	targetBased	343666	1267	0.734041769977036	3500
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Prolonged QT interval	targetBased	342084	3260	0.734041769977036	3500
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Bradycardia	targetBased	359207	1189	0.556882803103682	6
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Bradycardia	targetBased	63676	1938	0.556882803103682	6
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Bradycardia	targetBased	359207	316	0.556882803103682	6
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Bradycardia	targetBased	63656	2179	0.556882803103682	6
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Bradycardia	targetBased	359207	4555	0.556882803103682	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Bradycardia	targetBased	339297	1446	0.507645320472039	6
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Ventricular fibrillation	targetBased	305610	1552	0.407152792746921	42
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Ventricular fibrillation	targetBased	343666	1267	0.407152792746921	42
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Ventricular fibrillation	targetBased	342084	3260	0.407152792746921	42
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Abnormality of the cardiovascular system	targetBased	305610	3878	0.675190267140752	1550
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Abnormality of the cardiovascular system	targetBased	305610	1082	0.675190267140752	1550
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Abnormality of the cardiovascular system	targetBased	305610	1552	0.711592736821994	2381
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Abnormality of the cardiovascular system	targetBased	343666	1267	0.711592736821994	2381
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Abnormality of the cardiovascular system	targetBased	342084	3260	0.711592736821994	2381
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Abnormality of the cardiovascular system	pathwayBased	70898	707	0.481626628052691	19
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Abnormality of the cardiovascular system	pathwayBased	131324	544	0.481626628052691	19
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Abnormality of the cardiovascular system	targetBased	305610	2592	0.612683747155337	239
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Abnormality of the cardiovascular system	targetBased	335239	801	0.630409551474951	502
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Abnormality of the cardiovascular system	targetBased	335238	390	0.630409551474951	502
HTS of Smad transcription factor inhibitors	SMAD3	Abnormality of the cardiovascular system	targetBased	88033	251	0.406522914717714	73
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Abnormality of the cardiovascular system	targetBased	199169	715	0.569277510327076	411
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Abnormality of the cardiovascular system	targetBased	302297	1165	0.569277510327076	411
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	Abnormality of the cardiovascular system	targetBased	194628	267	0.536386687475283	104
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Abnormal heart morphology	pathwayBased	70898	707	0.53214174757145	9
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Abnormal heart morphology	pathwayBased	131324	544	0.53214174757145	9
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Patent ductus arteriosus	targetBased	316642	617	0.567131293854564	20
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Ischemic stroke	targetBased	335531	328	0.516525873530802	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Ischemic stroke	targetBased	339297	1446	0.436685419032319	8
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Ischemic stroke	targetBased	369953	760	0.312229359586519	12
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Ischemic stroke	targetBased	369953	498	0.312229359586519	12
Thrombin 1536 HTS	F2_modulation	Ischemic stroke	targetBased	217233	557	0.353397775729454	20
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Ventricular arrhythmia	targetBased	305610	1552	0.683101878753051	162
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Ventricular arrhythmia	targetBased	343666	1267	0.683101878753051	162
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Ventricular arrhythmia	targetBased	342084	3260	0.683101878753051	162
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Ventricular arrhythmia	targetBased	335239	991	0.439916790832495	8
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Ventricular arrhythmia	targetBased	335239	695	0.439916790832495	8
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Ventricular arrhythmia	targetBased	339297	1446	0.641084137971574	32
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Reduced left ventricular ejection fraction	targetBased	335531	328	0.563971467918354	9
HTS of Smad transcription factor inhibitors	SMAD3	Vascular dilatation	targetBased	88033	251	0.293136199956077	7
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Arrhythmia	targetBased	305610	1552	0.260133066682535	69
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Arrhythmia	targetBased	343666	1267	0.260133066682535	69
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Arrhythmia	targetBased	342084	3260	0.260133066682535	69
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	heart conduction disease	targetBased	305610	2592	0.271846747382295	290
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	short QT syndrome	targetBased	305610	3878	0.568605630843682	215
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	short QT syndrome	targetBased	305610	1082	0.568605630843682	215
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	short QT syndrome	targetBased	305610	1552	0.41039245993415	99
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	short QT syndrome	targetBased	343666	1267	0.41039245993415	99
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	short QT syndrome	targetBased	342084	3260	0.41039245993415	99
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	short QT syndrome	targetBased	305610	2592	0.443689779602828	318
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	essential hypertension	targetBased	335531	328	0.655030426761749	86
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	essential hypertension	targetBased	339297	1446	0.306714129819747	10
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	pericardial effusion	targetBased	330392	1295	0.284879239032575	8
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	arteriosclerosis disorder	targetBased	108286	1415	0.552064990371929	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	thrombotic disease	targetBased	86095	1442	0.286083808767426	13
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	thrombotic disease	targetBased	86095	1151	0.286083808767426	13
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	thrombotic disease	targetBased	369953	760	0.514268280638907	18
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	thrombotic disease	targetBased	369953	498	0.514268280638907	18
Thrombin 1536 HTS	F2_modulation	thrombotic disease	targetBased	217233	557	0.629548975281352	445
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	ventricular septal defect	targetBased	344733	7043	0.293378171058506	11
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Jervell and Lange-Nielsen syndrome	targetBased	305610	3878	0.829758025318848	193
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Jervell and Lange-Nielsen syndrome	targetBased	305610	1082	0.829758025318848	193
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	pulmonary hypertension	targetBased	360873	7438	0.295826525946821	9
qHTS of Nrf2 Activators	Nrf2 activators	pulmonary hypertension	pathwayBased	403871	1243	0.295826525946821	9
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	99314	335	0.307468927254904	180
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196176	782	0.307468927254904	180
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	99314	390	0.307468927254904	180
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196177	811	0.307468927254904	180
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196176	670	0.307468927254904	180
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	pulmonary hypertension	targetBased	196177	519	0.307468927254904	180
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	pulmonary hypertension	targetBased	76168	1231	0.514121558566674	17
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	pulmonary hypertension	targetBased	339674	2841	0.293303559901386	183
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	sinoatrial node dysfunction and deafness	targetBased	335531	328	0.798234352836398	89
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Brugada syndrome	targetBased	305610	3878	0.399136095092878	52
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Brugada syndrome	targetBased	305610	1082	0.399136095092878	52
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Brugada syndrome	targetBased	305610	1552	0.478699522092586	53
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Brugada syndrome	targetBased	343666	1267	0.478699522092586	53
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Brugada syndrome	targetBased	342084	3260	0.478699522092586	53
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	familial atrial fibrillation	targetBased	305610	3878	0.584915503283993	198
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	familial atrial fibrillation	targetBased	305610	1082	0.584915503283993	198
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	familial atrial fibrillation	targetBased	305610	2592	0.557484038987195	108
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	familial long QT syndrome	targetBased	305610	3878	0.858261017924304	1652
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	familial long QT syndrome	targetBased	305610	1082	0.858261017924304	1652
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	familial long QT syndrome	targetBased	305610	1552	0.810413609236612	888
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	familial long QT syndrome	targetBased	343666	1267	0.810413609236612	888
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	familial long QT syndrome	targetBased	342084	3260	0.810413609236612	888
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	familial long QT syndrome	targetBased	305610	2592	0.399973484574095	407
HTS of Smad transcription factor inhibitors	SMAD3	familial thoracic aortic aneurysm and aortic dissection	targetBased	88033	251	0.777860473513668	1211
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	coronary atherosclerosis	targetBased	339297	1446	0.577168330395272	6
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Romano-Ward syndrome	targetBased	305610	3878	0.917575767779804	689
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Romano-Ward syndrome	targetBased	305610	1082	0.917575767779804	689
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Romano-Ward syndrome	targetBased	305610	1552	0.93814629135582	1206
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Romano-Ward syndrome	targetBased	343666	1267	0.93814629135582	1206
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Romano-Ward syndrome	targetBased	342084	3260	0.93814629135582	1206
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Familial progressive cardiac conduction defect	targetBased	305610	3878	0.425086943408605	8
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Familial progressive cardiac conduction defect	targetBased	305610	1082	0.425086943408605	8
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Familial short QT syndrome	targetBased	305610	3878	0.764568393200508	60
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Familial short QT syndrome	targetBased	305610	1082	0.764568393200508	60
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Familial short QT syndrome	targetBased	305610	1552	0.828402105198518	351
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Familial short QT syndrome	targetBased	343666	1267	0.828402105198518	351
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Familial short QT syndrome	targetBased	342084	3260	0.828402105198518	351
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Familial short QT syndrome	targetBased	305610	2592	0.699555539533156	30
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	335239	801	0.622584838782076	123
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	335238	390	0.622584838782076	123
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	heart disease	pathwayBased	70898	707	0.267588911577723	55
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	heart disease	pathwayBased	131324	544	0.267588911577723	55
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	heart disease	targetBased	64908	1225	0.295511338182346	54
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	heart disease	targetBased	64908	359	0.295511338182346	54
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	heart disease	targetBased	194628	267	0.324902614329253	459
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	heart disease	targetBased	369953	2602	0.266850434050765	68
Factor XIa 1536 HTS	F11_modulation	vascular disease	targetBased	218707	302	0.261925524783603	92
Factor XIIa 1536 HTS	F12_modulation	vascular disease	targetBased	217430	649	0.29737794501814	65
HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat	MPI	vascular disease	targetBased	194152	656	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate	MPI	vascular disease	targetBased	194152	1288	0.307418870150215	258
HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.	MPI	vascular disease	targetBased	194152	814	0.307418870150215	258
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	congenital heart disease	targetBased	305610	3878	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	congenital heart disease	targetBased	305610	1082	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	congenital heart disease	targetBased	305610	2592	0.309305482466369	384
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Abnormal cardiovascular system physiology	targetBased	305610	3878	0.255900041100298	715
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Abnormal cardiovascular system physiology	targetBased	305610	1082	0.255900041100298	715
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Abnormal cardiovascular system physiology	targetBased	305610	1552	0.292071884654771	1238
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Abnormal cardiovascular system physiology	targetBased	343666	1267	0.292071884654771	1238
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Abnormal cardiovascular system physiology	targetBased	342084	3260	0.292071884654771	1238
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Abnormality of cardiovascular system electrophysiology	targetBased	305610	1552	0.291052991639106	1235
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Abnormality of cardiovascular system electrophysiology	targetBased	343666	1267	0.291052991639106	1235
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Abnormality of cardiovascular system electrophysiology	targetBased	342084	3260	0.291052991639106	1235
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	arterial disorder	targetBased	335531	328	0.263043575919809	683
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	arterial disorder	targetBased	339674	2841	0.307605371317295	175
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	heart conduction disease	targetBased	305610	3878	0.27147277959172	184
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	heart conduction disease	targetBased	305610	1082	0.27147277959172	184
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	cardiac rhythm disease	targetBased	305610	3878	0.278174095876582	223
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	cardiac rhythm disease	targetBased	305610	1082	0.278174095876582	223
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	cardiac rhythm disease	targetBased	305610	1552	0.280032584227586	211
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	cardiac rhythm disease	targetBased	343666	1267	0.280032584227586	211
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	cardiac rhythm disease	targetBased	342084	3260	0.280032584227586	211
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	cardiac rhythm disease	targetBased	305610	2592	0.297439427831753	156
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	cardiac rhythm disease	targetBased	335531	328	0.304830752442955	74
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	congenital anomaly of cardiovascular system	targetBased	305610	3878	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	congenital anomaly of cardiovascular system	targetBased	305610	1082	0.32583345778383	977
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	congenital anomaly of cardiovascular system	targetBased	305610	1552	0.270770606427675	331
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	congenital anomaly of cardiovascular system	targetBased	343666	1267	0.270770606427675	331
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	congenital anomaly of cardiovascular system	targetBased	342084	3260	0.270770606427675	331
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	congenital anomaly of cardiovascular system	targetBased	305610	2592	0.309305482466369	384
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2)	NR2F2	congenital anomaly of cardiovascular system	targetBased	369953	2602	0.266500325775173	60
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Glycogen storage disease with hypertrophic cardiomyopathy	targetBased	199169	715	0.305413139539117	1578
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Glycogen storage disease with hypertrophic cardiomyopathy	targetBased	302297	1165	0.305413139539117	1578
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Lysosomal disease with hypertrophic cardiomyopathy	targetBased	199169	715	0.305413139539117	1578
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Lysosomal disease with hypertrophic cardiomyopathy	targetBased	302297	1165	0.305413139539117	1578
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	Rare genetic cardiac disease	targetBased	305610	3878	0.314483144382057	259
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	Rare genetic cardiac disease	targetBased	305610	1082	0.314483144382057	259
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	Rare genetic cardiac disease	targetBased	305610	1552	0.319539417013411	532
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	Rare genetic cardiac disease	targetBased	343666	1267	0.319539417013411	532
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	Rare genetic cardiac disease	targetBased	342084	3260	0.319539417013411	532
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Rare genetic cardiac disease	targetBased	305610	2592	0.304986033813229	316
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Rare genetic cardiac disease	targetBased	199169	715	0.305534076087638	1590
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Rare genetic cardiac disease	targetBased	302297	1165	0.305534076087638	1590
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	199169	715	0.305428913809152	1579
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Rare familial disorder with hypertrophic cardiomyopathy	targetBased	302297	1165	0.305428913809152	1579

Some of these associations have also gone through clinical trials, as those in the graph below.

graph

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

table